Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
LSL Pharma Group Inc ( (TSE:LSL) ) just unveiled an announcement.
LSL Pharma Group Inc. reported record revenues of $6.6 million for Q1 2025, marking a 59% increase from the previous year, driven by a substantial 300% rise in CMO revenues. Despite a decline in eye-care revenues, the company achieved a positive EBITDA for the fifth consecutive quarter. The company completed the purchase of a new manufacturing line to boost production capacity and filed six new eye-care products with Health Canada. Additionally, LSL Pharma entered into strategic agreements to expand its eye-care pipeline, although it faces a court ruling related to plant relocation costs.
More about LSL Pharma Group Inc
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company that focuses on the development and manufacturing of eye-care products and contract manufacturing operations (CMO). The company is expanding its eye-care product portfolio and has recently integrated acquisitions to enhance its CMO platform.
Average Trading Volume: 41,667
Technical Sentiment Signal: Sell
For a thorough assessment of LSL stock, go to TipRanks’ Stock Analysis page.